Su Aan Goon

· Led the Respiratory & Immunology portfolio across launch and established brands in specialty and primary care.

· Successfully launched a new COPD inhaled therapy, delivering 102% of Year 1 target, and secured MOH listing within 18 months of commercialization.

· Accelerated portfolio performance through 24% Asthma volume growth and 33% biologic growth, outperforming market growth despite a competitive environment.

· Stabilized commercial operations and aligned team execution following organizational restructuring within three months of joining.

• Led the In-Market Brands business representing approximately 70% of Novartis Malaysia's revenue, overseeing established brands, strategic launches and Key Account Management.
• Delivered successful tender strategies despite increasing generic competition and evolving healthcare policies.
• Unified three commercial teams into a high-performing organization, achieving 111% of target with 12% growth in 2022, followed by 103% of target after the global organizational transformation.
• Improved commercial effectiveness through resource optimization, strategic prioritization and cross-functional business partnering.

· Led the Ophthalmology and Respiratory franchises, delivering sustained business growth despite the COVID-19 pandemic and MOH funding constraints.

· Successfully launched Pagenax, Enerzair and Atectura, while driving continued growth across established Respiratory and Retina portfolios.

· Repositioned the Retina portfolio to support strategic investment, leading the team to win the 2020 Global Lucentis Championship for the highest market share gain.

· Delivered award-winning commercial excellence, with the Respiratory franchise receiving the Top Brand Award (2019) and four awards in the 2020 Novartis Win as One Challenge.

· Integrated teams from different franchise cultures into a cohesive, high-performing organization during a period of strategic transformation.

• Led MSD's largest Cardiovascular & Metabolic business across Malaysia, Singapore and Brunei.
• Delivered 105% of budget across the cluster, with Malaysia achieving 6% growth despite challenging market dynamics, including tender losses and generic competition.
• Restored momentum for the Atozet launch following supply disruption while growing the Diabetes portfolio by 9% in a highly competitive market.
• Integrated commercial teams and led organizational restructuring to improve collaboration and execution.

• Led the Diabetes and Hypertension franchises, consistently exceeding annual business targets and delivering sustainable growth.
• Recognized with the Marketing Excellence Award (2014) and Merck Leader of the Year (2017) for outstanding commercial leadership.
• Built an award-winning marketing team, with the Diabetes franchise receiving the Marketing Excellence Award for four consecutive years (2015–2018).
• Drove digital transformation in commercial marketing, achieving global recognition for innovation and customer engagement.

· Led the Neuroscience and Neuromuscular business, delivering sustained double-digit growth while leading a high-performing sales and marketing team.

· Received Merck Leader of the Year (2013) and Marketing Excellence Awards (2012 & 2014) in recognition of commercial and leadership excellence.

· Recognized as the Asia Pacific subject matter expert for Neuromuscular marketing, supporting regional affiliates including Vietnam.

· Introduced innovative customer engagement through the company's 1st live surgical transmission workshop.

• Led the Neurosciences portfolio, successfully launching ReQuip PD within four months of joining and expanding market access through public and private sector initiatives.
• Recognized for strong performance with expanded responsibility for the Arixtra portfolio and leadership of the Neurosciences Product Manager.

• Led the Aprovel cardiovascular portfolio, delivering sustained double-digit growth through strategic brand management and commercialization.
• Successfully launched CoAprovel and led the pre-launch strategy for Multaq.
• Advanced market access by securing the first ARB AKK listing for Aprovel while contributing to national clinical practice guideline development.
• Built strong partnerships with healthcare professionals and professional societies through national disease awareness and scientific engagement initiatives.

• Built a strong commercial foundation managing diverse therapeutic portfolios across public and private healthcare sectors.
• Consistently achieved sales targets while developing extensive experience in stakeholder engagement across MOH, MOE and private healthcare institutions.